Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Atea Pharmaceuticals, Inc. | Chief Commercial Officer | Common Stock | 82.5K | $317K | $3.84 | Jan 31, 2024 | Held by John Vavricka as the Trustee of the John F. Vavricka Deed of Trust |
Atea Pharmaceuticals, Inc. | Chief Commercial Officer | Restricted Stock Units | 66.7K | $256K | $3.84 | Jan 31, 2024 | Direct |
Atea Pharmaceuticals, Inc. | Chief Commercial Officer | Common Stock | 21.5K | $82.7K | $3.84 | Feb 1, 2024 | Direct |
Atea Pharmaceuticals, Inc. | Chief Commercial Officer | Stock Option (Right to Buy) | 133K | Jan 31, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
AVIR | Atea Pharmaceuticals, Inc. | Jan 31, 2024 | 4 | -$45.4K | 4 | Feb 2, 2024 | Chief Commercial Officer |
AVIR | Atea Pharmaceuticals, Inc. | Jan 31, 2023 | 2 | $0 | 4 | Feb 2, 2023 | Chief Commercial Officer |
AVIR | Atea Pharmaceuticals, Inc. | Jan 31, 2022 | 1 | $0 | 4 | Feb 2, 2022 | Chief Commercial Officer |